A total of one year for trastuzumab, including the part with chemotherapy, adjuvant or neoadjuvant. The benefit from addition of pertuzumab, as might have been predicted, was very small, since it is very hard to add any sizable benefit to trastuzumab without some logical risk stratification; for ER ...

The addition of 1y of trastuzumab to anthracycline-taxane based chemotherapy conferred a relative approximately 50% improvement in DFS and a 33% improvement in overall survival in the pivotal joint North American study (Romond NEJM 2005). This study was recently updated after 8.4y of follow-up with ...